Abstract
The objective of this study was to elucidate an association between Apo- E4 allele and CSF biomarkers Aβ42 and tau for the diagnosis of Alzheimers Disease (AD) patients. Aβ42 and tau protein concentrations in CSF were measured by using ELISA assays. The levels of Aβ42 were found to be decreased where as tau levels increased in AD patients. Moreover in AD patients Apo-E4 allele carriers have shown low Aβ42 levels (328.86 ± 99.0 pg/ml) compared to Apo- E4 allele non-carriers (367.52 ± 57.37 pg/ml), while tau levels were higher in Apo-E4 allele carriers (511 ± 44.67 pg/ml) compared to Apo-E4 allele non-carriers (503.75 ± 41.08 pg/ml). Combination of Aβ42 and tau resulted in sensitivity of 75.38% and specificity of 94.82% and diagnostic accuracy of 84.30% for AD compared with the controls. Therefore low Aβ42 and elevated tau concentrations in CSF may prove to be a better diagnostic marker for AD along with the Apo-E4 allele.
Keywords: Alzheimer's disease, Aβ42, Tau, Apo-E4 allele, cerebrospinal fluid
Current Alzheimer Research
Title: Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Volume: 8 Issue: 2
Author(s): R. J.L. Kandimalla, S. Prabhakar, B. K. Binukumar, W. Y. Wani, N. Gupta, D. R. Sharma, A. Sunkaria, V. K. Grover, N. Bhardwaj, K. Jain and K. D. Gill1
Affiliation:
Keywords: Alzheimer's disease, Aβ42, Tau, Apo-E4 allele, cerebrospinal fluid
Abstract: The objective of this study was to elucidate an association between Apo- E4 allele and CSF biomarkers Aβ42 and tau for the diagnosis of Alzheimers Disease (AD) patients. Aβ42 and tau protein concentrations in CSF were measured by using ELISA assays. The levels of Aβ42 were found to be decreased where as tau levels increased in AD patients. Moreover in AD patients Apo-E4 allele carriers have shown low Aβ42 levels (328.86 ± 99.0 pg/ml) compared to Apo- E4 allele non-carriers (367.52 ± 57.37 pg/ml), while tau levels were higher in Apo-E4 allele carriers (511 ± 44.67 pg/ml) compared to Apo-E4 allele non-carriers (503.75 ± 41.08 pg/ml). Combination of Aβ42 and tau resulted in sensitivity of 75.38% and specificity of 94.82% and diagnostic accuracy of 84.30% for AD compared with the controls. Therefore low Aβ42 and elevated tau concentrations in CSF may prove to be a better diagnostic marker for AD along with the Apo-E4 allele.
Export Options
About this article
Cite this article as:
J.L. Kandimalla R., Prabhakar S., K. Binukumar B., Y. Wani W., Gupta N., R. Sharma D., Sunkaria A., K. Grover V., Bhardwaj N., Jain K. and D. Gill1 K., Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease, Current Alzheimer Research 2011; 8 (2) . https://dx.doi.org/10.2174/156720511795256071
DOI https://dx.doi.org/10.2174/156720511795256071 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Fibrinolytic Enzymes From Extremophilic Microorganisms in the Development of New Thrombolytic Therapies: Technological Prospecting
Recent Patents on Biotechnology Modulation of Rack-1/PKCβII Signalling By Soluble AβPPα in SH-SY5Y Cells
Current Alzheimer Research Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Effects of Flavonoids in Experimental Models of Arterial Hypertension
Current Topics in Medicinal Chemistry The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy
Current Alzheimer Research The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Relationship between CNS and Immunology: Correlation with Psychology
Current Drug Metabolism Astrocyte: An Innovative Approach for Alzheimer's Disease Therapy
Current Pharmaceutical Design Glucocorticoids, the Etiology of Obesity and the Metabolic Syndrome
Current Alzheimer Research Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia
Current HIV Research Delineating Somatostatins Neuronal Actions
Current Drug Targets - CNS & Neurological Disorders Meet Our Editorial Board Member:
Current Neuropharmacology Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
Vascular Disease Prevention (Discontinued) The Effects of Gender and CYP46 and Apo E Polymorphism on 24S-Hydroxycholesterol Levels in Alzheimers Patients Treated with Statins
Current Alzheimer Research